What we know about the new coronavirus infection in cancer patients

The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.

The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.

Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.

1. US Centers for Disease Control and Prevention (CDC). COVID-19 timeline. David J. Sencer CDC Museum. Available at: https://www.cdc.gov/museum/timeline/covid19.html (accessed on 31 August 2023).

2. https://coronavirus.jhu.edu/map.html

3. O’Driscoll M., Ribeiro Dos Santos G., Wang L., et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021;590 (7844):140–145. https://doi.org/10.1038/s41586-020-2918-0

4. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

5. Cortiula F., Pettke A., Bartoletti M., et al. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann of Oncol 2020;31 (5):553–555. https://doi.org/10.1016/j.annonc.2020.03.286

6. Practical recommendations of the Russian Society of Clinical Oncology for providing oncological care in the context of the COVID-19 pandemic. Available at: https: /  / rosoncoweb.ru / standarts / COVID-19 / (In Russ.)

7. Dai M., Liu D., Liu M., et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10 (6):783–791. https://doi.org/10.1158/2159-8290.CD-20-0422

8. Kuderer N. M., Choueiri T. K., Shah D. P., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395 (10241):1907–1918. https://doi.org/10.1016/S0140-6736(20)31187-9

9. Grivas P., Khaki A. R., Wise-Draper T. M., et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021;32 (6):787–800. https://doi.org/10.1016/j.annonc.2021.02.024

10. de Joode K., Dumoulin D. W., Tol J., et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer 2020;141:171–184. https://doi.org/10.1016/j.ejca.2020.09.027

11. Marta G. N., Bonadio R. C., Encinas Sejas O. N., et al. Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19. JCO Glob Oncol 2021;7:1084–1092. https://doi.org/10.1200/GO.21.00087

12. Passamonti F., Cattaneo C., Arcaini L., et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7 (10):e737e745. https://doi.org/10.1016/S2352-3026(20)30251-9

13. Pinato D. J., Zambelli A., Aguilar-Company J., et al. Clinical portrait of the SARS-CoV-2 epidemic in european patients with cancer. Cancer Discov 2020;10 (10):1465–1474. https://doi.org/10.1158/2159-8290.CD-20-0773

14. Williamson E. J., Walker A. J., Bhaskaran K., et al. Factors associated with COVID-19related death using OpenSAFELY. Nature 2020;584 (7821):430–436. https://doi.org/10.1038/s41586-020-2521-4

15. Lièvre A., Turpin A., Ray-Coquard I., et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer 2020;141:62–81. https://doi.org/10.1016/j.ejca.2020.09.035

16. Liang W., Guan W., Chen R., et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21 (3):335–337. https://doi.org/10.1016/S1470-2045(20)30096-6

17. Zhang L., Zhu F., Xie L., et al. Clinical characteristics of COVID-19infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31 (7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296

18. Bakouny Z., Hawley J. E., Choueiri T. K., et al. COVID-19 and cancer: current challenges and perspectives. Cancer Cell 2020;38 (5):629–646. https://doi.org/10.1016/j.ccell.2020.09.018

19. García L. F. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020;11:1441. https://doi.org/10.3389/fimmu.2020.01441

20. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395 (10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

21. Harvey W. T., Carabelli A. M., Jackson B., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021;19 (7):409–424. https://doi.org/10.1038/s41579-021-00573-0

22. Cheruiyot I., Kipkorir V., Ngure B., et al. Cancer is associated with coronavirus disease (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med 2021;45:179–184. https://doi.org/10.1016/j.ajem.2020.08.025

23. Huang Y., Yang C., Xu X-F., et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020;41 (9):1141–1149. https://doi.org/10.1038/s41401-020-0485-4

24. Yang K., Sheng Y, Huang C., et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21 (7):904–913. https://doi.org/10.1016/S1470-2045(20)30310-7

25. Tian J., Yuan X., Xiao J., et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21 (7):893–903. https://doi.org/10.1016/S1470-2045(20)30309-0

26. Crolley V. E., Hanna D., Joharatnam-Hogan N., et al. COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study. Ther Adv Med Oncol 2020;12:1758835920971147. https://doi.org/10.1177/1758835920971147

27. Lee L. Y., Cazier J. B., Starkey T., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395 (10241):1919–1926. https://doi.org/10.1016/S0140-6736(20)31173-9.